Testing whether people with BRAF V600 low-grade glioma can stop or slowly lower dabrafenib and trametinib
Official title: Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This trial looks at what happens when people who have been taking two targeted drugs stop them or slowly cut the dose back.
Read our full plain-language summary
What the trial team says
This phase II trial studies how well de-escalating the drugs dabrafenib and trametinib works in treating patients with low-grade gliomas that have a BRAF V600 gene mutation. Dabrafenib and trametinib are in a class of medications called kinase inhibitors. They work by blocking the action of abnormal proteins that signals tumor cells to multiply. This helps stop the spread of tumor cells. This trial may help doctors determine the best dosing strategy for patients who have received dabrafenib and trametinib for 12-24 months: Either stopping dabrafenib and trametinib completely or slowly reducing the dose for an additional 6 months.
Key facts
- Registry number
- NCT07110246
- Stage of testing
- Phase 2
- Conditions studied
- BRAF V600 Mutation, Low-grade Glioma, Low Grade Glioma of Brain, Recurrent Low Grade Glioma
Where it is running
This trial lists 9 sites.
-
Alabama
- University of Alabama at Birmingham (Birmingham)
-
California
- University of California, San Francisco (San Francisco)
-
District of Columbia
- Children's National Hospital (Washington D.C.)
-
Maryland
- John Hopkins Medical Center (Baltimore)
-
Missouri
- St. Louis Children's Hospital Washington University in St. Louis (St Louis)
-
New Jersey
- Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center (Hackensack)
-
North Carolina
- Duke University Medical Center (Durham)
-
Tennessee
- St. Jude Children's Research Hospital (Memphis)
-
Utah
- University of Utah (Salt Lake City)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.